InterCure Ltd. (NASDAQ:INCR – Get Free Report) was the target of a significant drop in short interest during the month of June. As of June 30th, there was short interest totaling 15,144 shares, a drop of 67.9% from the June 15th total of 47,234 shares. Based on an average trading volume of 104,980 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the company’s shares are sold short.
InterCure Trading Down 1.0%
Shares of NASDAQ INCR traded down $0.01 during midday trading on Friday, hitting $0.97. The stock had a trading volume of 3,609 shares, compared to its average volume of 93,334. The company has a quick ratio of 0.97, a current ratio of 1.48 and a debt-to-equity ratio of 0.20. InterCure has a 1-year low of $0.68 and a 1-year high of $1.77. The company has a market capitalization of $53.04 million, a price-to-earnings ratio of 32.33 and a beta of 1.39. The company has a fifty day moving average price of $0.95 and a 200 day moving average price of $0.90.
InterCure (NASDAQ:INCR – Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $23.15 million for the quarter.
Analyst Upgrades and Downgrades
Check Out Our Latest Research Report on INCR
About InterCure
InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.
Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.
Featured Stories
- Five stocks we like better than InterCure
- 3 Rare-Earth ETFs That Help Investors Balance Exposure and Risk
- Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
- Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
- This Dividend ETF Choice Could Shape Your Income Strategy Through 2026
Receive News & Ratings for InterCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InterCure and related companies with MarketBeat.com's FREE daily email newsletter.
